Compare Direxion Daily S&P 500 Bull 3X Shares (SPXL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily S&P 500 Bull 3X Shares vs Travere Therapeutics Inc. Common Stock — how do they compare? Direxion Daily S&P 500 Bull 3X Shares trades at $283.61 (market cap $7.36B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Direxion Daily S&P 500 Bull 3X Shares is the larger of the two by market cap, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily S&P 500 Bull 3X Shares for 33 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SPXL | TVTX | |
|---|---|---|
Market Cap | $7.36B | $4.88B |
Volume | 1,127,892 | 1,668,577 |
Sector | Leveraged / Inverse | Health |
52-Week High | $301.38 | $67.52 |
52-Week Low | $170.20 | $26.79 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPXL trades at $297.37 with no daily change, maintaining a bullish technical stance supported by moving averages. The ETF shows neutral oscillator signals with RSI at 75.74 suggesting potential overbought conditions. Recent news highlights S&P 500 valuation concerns amid strong profit growth expectations of 35% for 2026, though projections slow to 15% for 2027 according to Wall Street analysts.
The ETF's outlook remains tied to S&P 500 performance, with seasonal patterns and earnings growth as key catalysts. Risks include market concentration in top holdings and geopolitical uncertainty. Analyst sentiment is mixed with technical indicators favoring upside while fundamental valuations warrant caution given projected earnings deceleration.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
